Hydrochlorothiazide News

Hydrochlorothiazide , the most commonly employed blood-pressure-lowering drug in the US, used at the usual doses prescribed - 12.5 mg to 25 mg/per day - is a "paltry" antihypertensive, inferior to all other drug classes, and there is no published evidence that it reduces heart attack or stroke [ 1 ]. These are the controversial conclusions of a new ...

From the Vascular Biology and Hypertension Program, Sleep/Wake Disorders Center, University of Alabama at Birmingham ; Centre Hpitalier de l'Universit Laval , Ste-Foy, Qubec, Canada; and Novartis Pharmaceuticals Corporation , East Hanover, NJ.

Olmetec gives physicians new option to achieve earlier blood pressure reduction MONTREAL, May 21 /CNW/ - Physicians who treat any of the five million-plus Canadians with high blood pressure , often referred to as the 'silent killer', now have a better option to aggressively treat the condition using a new angiotensin receptor blocker .

Amlodipine is a calcium-channel blocker. Valsartan is an angiotensin-receptor blocker .

Video: FDA approves Exforge HCT - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill - Exforge HCT combines a proven calcium channel blocker, angiotensin receptor blocker and diuretic in one pill - In a clinical trial, Exforge HCT demonstrated significantly greater reductions in systolic and diastolic BP, compared ...

Nippon Boehringer Ingelheim Co., Ltd. and Astellas Pharma Inc. announced today that on 22 April the approval of manufacture and marketing of MicombiCombination Tablets was obtained.

To the Editor: In their report on the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension trial, Jamerson et al.

Ranbaxy Pharmaceuticals Inc. , a wholly owned subsidiary of Ranbaxy Laboratories Limited , announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market ...

COLORADO SPRINGS: American swimmer Emily Brunemann has been slapped with a six-month suspension after testing positive for a banned substance, the United States Anti-doping Agency announced Wednesday.

DRUG NEWS: Calcium channel blocker outperforms diuretic Combining benazepril, an angiotensin-converting enzyme inhibitor, with amlodipine, a calcium channel blocker, may dramatically reduce the risk of ...

From the Division of Cardiology, St Luke's and Roosevelt Hospitals, Columbia University College of Physicians and Surgeons, New York, NY , and Division of Cardiology, Brigham and Women's Hospital, Boston, Mass ...

ECARD is a tablet taken orally once daily and the two approved formulations are "ECARD LD" and "ECARD HD"; 4mg candesartan cilexetil / 6.25mg hydrochlorothiazide and 8mg candesartan cilexetil / 6.25mg ...

Novartis AG said Wednesday it has received approval in Japan to market four drugs to treat asthma, cancer, hypertension and blindness.

From the Department of Nephrology and Hypertension, University of Erlangen-Nrnberg, Erlangen, Germany ; Department of Nephrology, University Hospital, Essen, Germany ; Department of Nephrology, Hospital San ...

CiteULike is a free online bibliography manager. Register and you can start organising your references online.

This was a high risk population of hypertensives. The study was published in NEJM.

Combination therapy with the angiotensin-converting enzyme inhibitor benazepril and the calcium-channel blocker amlodipine is superior to the treatment combination of benazepril and the diuretic ...

DRUG NEWS: Drug duo reduces mortality in older adults Current guidelines call for using a thiazide diuretic alone as the initial treatment for hypertension.

A new study suggests that doctors may want to try different drugs first to treat high blood pressure.

Pairing an ACE inhibitor with a calcium channel blocker, rather than a diuretic, may offer greater cardiovascular benefit to hypertensive patients, reports the New England Journal of Medicine .